Nico C. B. de Jager

Nico C. B. de Jager

Auto-generated profile, based on publicly available information

Nico C. B. de Jager

Department of Hospital Pharmacy – Clinical Pharmacology Amsterdam UMC University of Amsterdam Amsterdam The Netherlands

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2018 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
SDSven C. van Dijkman
Sven C. van Dijkman
NJNico C. B. de Jager
Nico C. B. de Jager
WRWillem M. Rauwé
Willem M. Rauwé
MDMeindert Danhof
Meindert Danhof
OPOscar Della Pasqua
Oscar Della Pasqua

24 March 2018 in Haemophilia
Verified
Journal Article
Open access
PDF file
HHH. C. A. M. Hazendonk
H. C. A. M. Hazendonk
JHJ. M. Heijdra
J. M. Heijdra
NJN. C. B. de Jager
N. C. B. de Jager
HVH. C. Veerman
H. C. Veerman
JBJ. Boender
J. Boender
TGthe “OPTI‐CLOT” and “WIN” study group
the “OPTI‐CLOT” and “WIN” study group
Introduction: Patients with Von Willebrand disease (VWD) are regularly treated with VWF‐containing concentrates in case of acute bleeding, trauma and dental or surgical procedures.Aim: In this multicentre retrospective study, current perioperative management with a von Willebrand factor (VWF)/Factor VIII (FVIII) concentrate (Haemate® P) in patients with VWD was evaluated.Patients/Methods: Patients with VWD undergoing minor or major surgery between 2000 and 2015, requiring treatment with a VWF/FVIII concentrate (Haemate® P), were included. Achieved VWF activity (VWF:Act) and FVIII during FVIII‐based treatment regimens were compared to predefined target levels in national guidelines.Results: In total, 103 patients with VWD (148 surgeries) were included: 54 type 1 (73 surgeries), 43 type 2 (67 surgeries) and 6 type 3 (8 surgeries). Overall, treatment resulted in high VWF:Act and FVIII levels, defined as ≥0.20 IU/mL above predefined levels. In patients with type 1 VWD, respectively, 65% and 91% of trough VWF:Act and FVIII levels were higher than target levels. In patients with type 2 and type 3 VWD, respectively, 53% and 57% of trough VWF:Act and 72% and 73% of trough FVIII levels were higher than target level. Furthermore, FVIII accumulation over time was observed, while VWF:Act showed a declining trend, leading to significantly higher levels of FVIII than VWF:Act.Conclusion: High VWF:Act and accumulation of FVIII were observed after perioperative FVIII‐based replacement therapy in patients with VWD, both underlining the necessity of personalization of dosing regimens to optimize perioperative treatment.

3 August 2020 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
NJNico C. B. de Jager
Nico C. B. de Jager
JHJessica M. Heijdra
Jessica M. Heijdra
QKQuincy Kieboom
Quincy Kieboom
MKMarieke J. H. A. Kruip
Marieke J. H. A. Kruip
FLFrank W. G. Leebeek
Frank W. G. Leebeek
FGfor the OPTI-CLOT Group
for the OPTI-CLOT Group
Objective Most von Willebrand disease (VWD) patients can be treated with desmopressin during bleeding or surgery. Large interpatient variability is observed in von Willebrand factor (VWF) activity levels after desmopressin administration. The aim of this study was to develop a pharmacokinetic (PK) model to describe, quantify, and explain this variability. Methods Patients with either VWD or low VWF, receiving an intravenous desmopressin test dose of 0.3 µg kg−1, were included. A PK model was derived on the basis of the individual time profiles of VWF activity. Since no VWF was administered, the VWF dose was arbitrarily set to unity. Interpatient variability in bioavailability (F), volume of distribution (V), and clearance (Cl) was estimated. Results The PK model was developed using 951 VWF activity level measurements from 207 patients diagnosed with a VWD type. Median age was 28 years (range: 5–76), median predose VWF activity was 0.37 IU/mL (range: 0.06–1.13), and median VWF activity response at peak level was 0.64 IU/mL (range: 0.04–4.04). The observed PK profiles were best described using a one-compartment model with allometric scaling. While F increased with age, Cl was dependent on VWD type and sex. Inclusion resulted in a drop in interpatient variability in F and Cl of 81.7 to 60.5% and 92.8 to 76.5%, respectively. Conclusion A PK model was developed, describing VWF activity versus time profile after desmopressin administration in patients with VWD or low VWF. Interpatient variability in response was quantified and partially explained. This model is a starting point toward more accurate prediction of desmopressin dosing effects in VWD. N.d.J. wrote the manuscript. J.H. and Q.K. collected the clinical data. N.d.J. and R.M. performed the analyses and developed the empirical population PK model. M.C. supervised data collection. R.M. and M.C. jointly supervised this study, while F.L. and M.K. gave critical guidance. All authors contributed substantially to the critical revision of the manuscript, and approved the final draft. * Both are first authors. ** Both are last authors. † See [Supplementary Appendix A] for a full list of members of the study group.

8 May 2022 in Haemophilia
Verified
Journal Article
Open access
JHJessica M. Heijdra
Jessica M. Heijdra
MCMichael E. Cloesmeijer
Michael E. Cloesmeijer
NJNico C.B. de Jager
Nico C.B. de Jager
FLFrank W.G. Leebeek
Frank W.G. Leebeek
MKMarieke Kruip
Marieke Kruip
FCfor the OPTI‐CLOT/ To WiN study group and SYMPHONY consortium
for the OPTI‐CLOT/ To WiN study group and SYMPHONY consortium
Desmopressin can be used to prevent bleeding in von Willebrand disease (VWD), but the relationship between desmopressin and von Willebrand factor activity (VWF:Act) has yet to be quantified. To quantify the relationship between desmopressin dose, its plasma concentration and the VWF:Act response in type 1 VWD patients. Forty-seven VWD patients (median age 25 years, IQR: 19-37; median body weight 71 kg, IQR: 59-86) received an IV desmopressin dose of .3 mcg/kg. In total, 177 blood samples were available for analysis. We developed an integrated population pharmacokinetic-pharmacodynamic (PK-PD) model using nonlinear mixed effect modelling. Subsequently, we performed Monte Carlo simulations to investigate the efficacy of the current dosing regimen. A one-compartment PK model best described the time profile of the desmopressin concentrations. In the PD turnover model, the relationship between desmopressin plasma concentration and release of VWF:Act from the vascular endothelium was best described with an Emax model. Typically, VWF:Act increased 452% with an EC50 of .174 ng/ml. Simulations demonstrated that after .3 mcg/kg desmopressin intravenously, >90% patients with a VWF:Act baseline of ≥.20 IU/mL attain a VWF:Act >.5 IU/ml up to ≥4 h after administration. A capped dose of 30 mcg was sufficient in patients weighing over 100 kg. The relationship between desmopressin and VWF:Act was quantified in a PK-PD model. The simulations provide evidence that recently published international guidelines advising an intravenous desmopressin dose of .3 mcg/kg with a capped dose of 30 mcg > 100 kg gives a sufficient desmopressin response.